Johnson & Johnson's Q1 2012 earnings call provided a mix of signals for investors. The company managed to exceed earnings expectations despite challenges in the U.S. market, attributed to generic competition for key drugs, demonstrating resilience. New product launches and expansions abroad, along with updates on promising drugs like ZYTIGA, suggest a positive outlook for long-term growth. However, ongoing issues like OTC product recalls, significant legal uncertainties, and segment-specific growth challenges pose short-term risks. Given these factors, a neutral market reaction over the next 1-2 weeks is anticipated.

[0]